記事

Sanofi: Forwarding Medical Advances and Breakthroughs to Help People Have Better Health

Faster time to market in any industry is vital, but in bio-pharmaceuticals, it is even more than that.

Katherine Knowles-Marchione
Katherine Knowles-Marchione
2017年6月11日 3 分で読める
bio-pharmacology and data analytics

Faster time to market in any industry is vital, but in bio-pharmaceuticals, it is even more than that – faster time to market can improve patient care or even change patient outcomes.  For the French multi-national bio-pharmaceutical Sanofi, analytics and data are the key factor in accelerating time to market. Operating in 100 countries around the globe and providing healthcare solutions to more than 170 countries, Sanofi produces critical pharma products for oncology, diabetes, cardiovascular, central nervous system and vaccines.

Screen-Shot-2017-06-12-at-5-57-19-PM-300x168-(1).png

Our goal is to help people have better health.  We produce vaccines to prevent disease in some of the poorest countries in the world.  We are researching solutions to meet unmet needs. We are also in consumer health, helping people feel better and live better.  We provide this to people all around the world.

– Martin Longpré, Solution Architect
"The goal is to help people have better health. We produce vaccines to prevent disease in some of the poorest countries in the world. @Sanofi is researching solutions to meet unmet needs."

It is well recognized that clinical data is one of the most sensitive industry assets and a competitive advantage that is required for critical evidence of a drug therapy’s efficacy, safety, as well as potential health and economic impact. Managing one of the largest R&D organizations in the bio-pharmaceutical industry, with a diverse pipeline, Sanofi R&D focuses on maximizing the efficiency of its clinical development organization as well as improving visibility into the progress of its global trials. Aiming toward the business outcomes of product innovation and risk mitigation, Sanofi R&D created MAESTRO.  Like a distinguished musician, MAESTRO is an agile, integrated warehouse designed to scale and address the clinical trial challenges that materialize from the high variability of the data captured.  Clinical trial data is as varied as it gets; everything must be entered – patient data, medical test results, protocol data, and medical side effects (even a headache must be captured).

Screen-Shot-2017-06-12-at-5-57-08-PM-300x168-(1).png

MAESTRO, from the beginning was designed to scale.  Today, the solution is able to address the clinical trial challenges materialized by the high variability of the data captured and the continuous increase in volume introduced by an extensive portfolio of prescription drugs, vaccines, generics, and consumer healthcare products.  Sanofi R&D is able to manage dozens of studies at once (70-75) with the ability to scale to 200.  Researchers are able to refresh the study every ten minutes rather than every forty in the previous environment, allowing them faster access to new information.  And, the lockout time on studies has been reduced from eight hours to just under an hour!

If we think about this system, it allows us to recognize and rapidly address any change in the status of a patient. If a patient experiences an adverse event during a clinical study, especially a serious adverse event, it is important that we get notified immediately so we can respond accordingly. The safety of our patients always comes first, in all the studies we do.

– Martin Longpré, Solution Architect

Teradata’s Enterprise Data Consulting organization helped Sanofi architect, integrate and migrate the data from Oracle to Teradata in addition to being instrumental in implementing important features such as JSON, User Defined Functions and Temporal. Project MAESTRO is impacting business outcomes, including;

  • Product Innovation and the ability of the R&D organization to potentially create new products or designs that are safer, more efficient, and meet the market needs sought by doctors and patients.
  • Risk identification, mitigation and evaluation should any agency (internal or external) want to understand a study’s traceability.

The major advantage is that we have a history of all the interactions with the patient.  This means from the beginning of the clinical study, let’s say four years ago, to the end of the study, we will be able to provide every action that has taken place with that subject for all the different elements of the study.

– Martin Longpré, Solution Architect

All of which propels Sanofi towards their mission to “shape tomorrow’s health.”

“Félicitations” to Sanofi on project MAESTRO and all of your success!

Tags

会社情報 Katherine Knowles-Marchione

Teradata’s customers are changing the world by finding answers to the toughest challenges and powering the new era of Pervasive Data Intelligence. Katherine Knowles-Marchione leads Teradata’s Global Customer Engagement and Advocacy team who is laser focused on creating opportunities for the voice of our customers to tell their story. She brings more than 25 years of technology and industry business expertise. With sales and marketing expertise, Katherine and her team uncover innovative solutions that detail business use-cases with measurable results by conversing with global customers encompassing people, process, and technology.
 

すべての投稿の表示 Katherine Knowles-Marchione

最新情報をお受け取りください

メールアドレスをご登録ください。ブログの最新情報をお届けします。



テラデータはソリューションやセミナーに関する最新情報をメールにてご案内する場合があります。 なお、お送りするメールにあるリンクからいつでも配信停止できます。 以上をご理解・ご同意いただける場合には「はい」を選択ください。

テラデータはお客様の個人情報を、Teradata Global Privacy Policyに従って適切に管理します。